deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02317705

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

Sponsor: On Target Laboratories, LLC

Conditions Ovarian Cancer
Interventions Laparotomy Near infrared camera imaging system OTL38
Updated 10 times since 2017 Last updated: May 24, 2022 Started: Dec 31, 2014 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by On Target Laboratories, LLC and has accumulated 10 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Oct 2019 · 16 months · monthly snapshotCompleted~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotCompleted~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotCompleted~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshotCompleted~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2022 [monthly]

    Completed PHASE2

  5. Oct 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE2

  2. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Oct 2019 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • On Target Laboratories, LLC
  • SynteractHCR
Data source: On Target Laboratories, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations